Eisai May Resubmit Aricept Severe Alzheimer’s sNDA In Electronic Format
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai is considering an electronic format for a mid-December resubmission of an sNDA for Aricept treatment of severe Alzheimer’s disease.